AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 312.5 USD | -0.71% |
|
+0.75% | +8.49% |
| Sales 2024 * | 33.01B 2,599B | Sales 2025 * | 33.98B 2,675B | Capitalization | 168B 13,197B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.13B 325B | Net income 2025 * | 6.61B 520B | EV / Sales 2024 * | 6.55 x |
| Net Debt 2024 * | 48.47B 3,816B | Net Debt 2025 * | 43.51B 3,426B | EV / Sales 2025 * | 6.21 x |
| P/E ratio 2024 * |
40.4
x | P/E ratio 2025 * |
24.9
x | Employees | 26,700 |
| Yield 2024 * |
2.97% | Yield 2025 * |
3.2% | Free-Float | 99.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Amgen Inc.
More recommendations
More press releases
More news
| 1 day | -0.71% | ||
| 1 week | +0.75% | ||
| Current month | +14.07% | ||
| 1 month | +16.19% | ||
| 3 months | +10.14% | ||
| 6 months | +17.74% | ||
| Current year | +8.49% |
1 week
307.47
321.44
1 month
265.72322.60
Current year
260.68329.72
1 year
211.71329.72
3 years
198.64329.72
5 years
166.68329.72
10 years
111.96329.72
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 31/05/06 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 22/10/19 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 12-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 02/02/17 |
Ellen Kullman
BRD | Director/Board Member | 68 | 13/10/16 |
Robert Williams
BRD | Director/Board Member | 75 | 16/10/14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 116 M€ | +17.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/05/24 | 312.5 | -0.71% | 1,974,222 |
| 16/05/24 | 314.7 | -1.35% | 2,367,819 |
| 15/05/24 | 319 | +2.45% | 3,466,160 |
| 14/05/24 | 311.4 | +0.96% | 1,631,250 |
| 13/05/24 | 308.4 | -0.55% | 1,558,472 |
Delayed Quote Nasdaq, May 17, 2024 at 09:00 pm
More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
312.5
USD
Average target price
314.1
USD
Spread / Average Target
+0.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.49% | 168B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| -0.52% | 162B |
- Stock Market
- Equities
- AMGN Stock
